Market Snapshot

BSE Sensex: 83576.24 -0.72%
BSE 500: 36807.62 -0.89%
BSE 200: 11620.53 -0.79%
BSE 100: 26904.82 -0.73%
BSE MidCap: 46304.8 -0.90%
BSE SmallCap: 49912.11 -1.74%
BSE BANKEX: 66616.92 -0.58%
BSE IT: 36795.24 0.03%
Nifty 50: 25683.3 -0.75%
Nifty 500: 23467.35 -0.90%
Nifty 200: 14306.95 -0.79%
Nifty 100: 26252.95 -0.79%
Nifty Midcap 100: 59748.15 -0.79%
Nifty Small 100: 17282.65 -1.81%
Nifty IT: 38027.2 0.28%
Nifty PSU Bank: 8601.05 0.18%

News:

Protean eGov Technologies bags...
PTC Industries? arm secures ma...
Globus Spirits reports multi-f...
IREDA Q3 PAT jumps 15% YoY to ...
Tejas Networks reports dismal ...

Aarti Pharmalabs Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

09 Jan 2026 | 04:14 PM

761.75

31.40 (4.30%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

15.39%

Return (1Y)

Beaten Nifty 50 by 6.22%
More Volatile

2.86%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.13%
Not so consistent

5/12

Months

underperformed Nifty 50
AxisDirect View

No View

52 Week High-Low

971

568

News & Announcements

Aarti Pharmalabs slides after Q2 PAT tumbles 49% YoY to Rs 28 cr
62 days ago

Aarti Pharmalabs slides after Q2 PAT tumbles 49% YoY to Rs 28 cr

10 - Nov - 2025 12:00 | 62 days ago

Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025.
Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year.
Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review.
On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25.
Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.
Powered by Capital Market - Live News
Aarti Pharmalabs consolidated net profit declines 48.88% in the September 2025 quarter
62 days ago

Aarti Pharmalabs consolidated net profit declines 48.88% in the September 2025 quarter

10 - Nov - 2025 12:00 | 62 days ago

Net profit of Aarti Pharmalabs declined 48.88% to Rs 27.92 crore in the quarter ended September 2025 as against Rs 54.62 crore during the previous quarter ended September 2024. Sales declined 8.67% to Rs 418.33 crore in the quarter ended September 2025 as against Rs 458.03 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 418.33 458.03 -9

OPM % 17.71 20.45 -

PBDT 63.46 92.65 -32

PBT 38.69 71.77 -46

NP 27.92 54.62 -49

Powered by Capital Market - Live News
Aarti Pharmalabs to declare Quarterly Results
75 days ago

Aarti Pharmalabs to declare Quarterly Results

28 - Oct - 2025 12:00 | 75 days ago

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 November 2025.
Powered by Capital Market - Live News
Aarti Pharmalabs gains on commissioning phase 1 of new Gujarat facility
130 days ago

Aarti Pharmalabs gains on commissioning phase 1 of new Gujarat facility

03 - Sep - 2025 12:00 | 130 days ago

According to an exchange filing, the company confirmed that it has received all necessary approvals and permissions to commence operations at the site. Phase 1 includes a total reactor capacity of 440 kilolitres (kL), with 63 reactors.
The greenfield facility spans 80 acres and is designed for significant scalability, with potential to expand capacity up to 8?10 times that of Phase 1 in the future.
Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.
The company reported a 10.73% decline in consolidated net profit to Rs 49.50 crore in Q1 FY26, compared to Rs 55.45 crore posted in Q1 FY25. Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Aarti Pharmalabs Ltd has increased by 9.12% since past 3 Months
MF shareholding in Aarti Pharmalabs Ltd has decreased by -12.16% since past 3 Months
FII shareholding in Aarti Pharmalabs Ltd has increased by 8.68% since past 1 Year
MF shareholding in Aarti Pharmalabs Ltd has decreased by -83.95% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	418.33	458.03	-9
OPM %	17.71	20.45	-
PBDT	63.46	92.65	-32
PBT	38.69	71.77	-46
NP	27.92	54.62	-49

General Notifications

My Notifications

Research Notifications

Aarti Pharmalabs Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

761.75 31.40 (4.30%)

News & Announcements

Price vs Volume

Stock Trivia

Aarti Pharmalabs Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

761.75

31.40 (4.30%)